Formulations - Branded
Ipca manufactures over 350 formulations in virtually every dosage form: oral solids and liquids, dry powders for suspension, and injectables (liquid and dry). Our finished formulations are available in over 500,000 retail shops that are catered to by a network of over 1500 wholesalers. 4000 sales and marketing personnel service over 200,000 doctors across the country.
We have leading brands in 5 therapeutic areas, with 4 of our branded formulations being ranked among the Top-300 Indian brands by ORG-IMS.
Our top 10 brands are Zerodol (Aceclofenac + combinations), Lariago (Chloroquine), HCQS (Hydroxychloroquine), Perinorm (Metoclopramide), Rapither (Artemotil), Tenoric (Atenolol + Chlorthalidone), Lumerax (Artemether + Lumefantrine), Etova (Etodolac), Malirid (Primaquine) and Folitrax (Methotrexate).
As part of Ipca's marketing segmentation strategy for India, specialty-focused marketing divisions were conceived a couple of years ago. Today, these 12 divisions are paying rich dividends.
Brands like Glycinorm, HCQS, Lariago, Malirid, Movon, Pari, Perinorm, Ramcor, Solvin, Sultax, Tenolol, Tenoric, and Zerodol have become brand leaders in their respective therapeutic segments, and 4 of these are also rated among the Top-300 Indian Brands (all categories) by ORG-IMS.
This division focuses on the cardiovascular and anti-diabetic segments in markets that have the potential for high-end medication. 3C is making its presence felt by catering to the growing needs of specialist doctors in these markets. Leading brands include Revelol AM (Metoprolol + Amlodipine), Revelol H (Metoprolol + Hydrochlorothiazide), Glycinorm (Gliclazide), Glycinorm Total (Gliclazide + Metformin + Pioglitazone), Revelol (Metoprolol) and Ramcor (Ramipril).
The 3D division strengthens Ipca presence in the cardio-diabetic segment with major focus on lipids management and dose-titration. Xtor (Atorvastatin), the flagship brand, is well supported by other brands like Piomed (Pioglitazone), Piomed M (Pioglitazone + Metformin), Piomed MG (Pioglitazone + Metformin + Glimepiride), Calchek (Amlodipine), Tenochek (Amlodipine + Atenolol) and Isordil (Isosorbide Dinitrate). Seeking newer approaches to hypertension management, this division is pioneering clinical studies with low-dose Chlorthalidone.
India's first specialty division dedicated to the needs of rheumatologists and orthopaedicians, Activa has attained a distinct leadership position in rheumatology with 46% market-share. The division markets a growing portfolio of dynamic brands like HCQS (Hydroxychloroquine Sulphate), Folitrax (Methotrexate), Saaz (Sulfasalazine) and MMF (Mycophenolate Mofetil). Today, HCQS is rated among the Top-300 Indian brands by ORG-IMS while a relatively new star Zaltokin (Zaltoprofen), enjoys a first-mover advantage in the pain management segment. Ebuxo (Febuxostat) is another up-coming brand for gout management.
This division caters to the needs of intensivists, both surgical and non-surgical, with a basket of oral and injectable antibiotics. Altus made its presence felt with Keftragard (Cefatrixone + Sulbactam) followed by the world's first Gardcef (Ceftazidime + Sulbactam). Today, Lactagard (Cefoperazone + Sulbactam) is the leading brand. Other prominent brands include Tazofast (Piperacillin + Tazobactam) and Fastclav (Clavulanic Acid + Cefuroxime Axetil).
One of the fastest growing divisions of Ipca, Bionova's focus area is dermatology. It has already made its mark by leading in the oral anti-acne segment with brands like Azifast (Azithromycin) and Acutret (Isotretinoin). With its latest topical corticosteroid Halotop (Halobetasol Propionate), Bionova has entered mainstream dermatology. And with the launch of Cutinorm bathing bar, entrenchment in derma-cosmeceuticals is not too far away.
This division offers a wide basket of trusted remedies to help doctors for first-line treatments. The portfolio diversifies into cardiovascular, gastro-intestinal, anti-bacterial, pain management and respiratory segments. Perinorm (Metoclopramide HCl) and Tenoric (Atenolol + Chlorthalidone) are the #1 brands in their respective segment with Perinorm featuring among the Top-300 Indian brands by ORG-IMS. Other major brands include Tenolol (Atenolol), Eltocin (Erythromycin) and Nemocid (Pyrantel Pamoate).
This cardio-diabetic division caters to the growing needs of cardiologists and diabetologists. Hycare markets all major molecules for the management of cardiovascular diseases, Type II diabetes and its related complications. Some leading brands are Glyree (Glimepiride), Glyree-M (Glimepiride + Metformin), Glyree-MP (Pioglitazone + Metformin + Glimepiride), Losanorm (Losartan), Telminorm (Telmisartan), Pleotor (Atorvastatin), Zilast (Cilostazole) and Clopact (Clopidogrel).
Innova marks Ipca's entry into the neuropsychiatry segment. Several firsts to its credit include world's first Quel SR (Quetiapine Sustained Release), India's first and only Inspiral SR (Methylphenidate Sustained Release) and India's first patent-filed Pari CR (Paroxetine Controlled Release).
Ipca's second largest division, Intima nurtures the largest number of anti-malarial brands that have helped Ipca hold undisputed leadership in this segment with a market-share of over 34%. With well-entrenched brands in the gastro-intestinal and anti-pyretic segment, it has now forayed into the cough and NSAIDs market. Intima's star brands Lariago (Chloroquine Phospate), Rapither-AB (Alpha-Beta Artemether) and Lumerax (Artemether + Lumefantrine) feature in the Top-300 Indian brands by ORG-IMS. The latter also enjoys a first-mover advantage in its segment. Other leading brands include Larinate (Artesunate), Malirid (Primaquine) and Pacimol(Paracetamol).
Ipca's newest division, it caters to one of the fastest growing areas in the market - pain management. Lead brands include India's first Etodolac - Etova, India's first Aceclofenac - Movon, DFZ (Deflazacort), Calten (Calcitriol + Calcium Carbonate + Zinc), India's first disease-modifying drug for osteoarthritis - Diasol (Diacerein), Nilitis (Nabumetone), Celedol (Celecoxib) and Thiofast (Thiocholchicoside).
Pharma is Ipca's flagship division handling the largest number of brands. It focuses on multi-specialty areas like pain, cardiovascular, gastro-intestinal, anti-infective and cough. This division hosts many multi-crore brands and enjoys leadership in the pain segment. Zerodol is the first Acelofenac launched in India, and is among the fastest growing brands in the NSAID segment. Solvin (Phenylephrine + Bromhexine), Azibact (Azithromycin), Vinicor (Metoprolol) are some of the other leading brands. Promising brands in the portfolio include Rx Plus, a nutraceutical combination of natural extracts, minerals, vitamins and amino acids, and Electrosip, an enriched ORS.
This super-specialty, urology-focused division addresses several geriatric diseases like BPH, overactive bladder and calculi. Lead brands include Tasulin (Tamsulosin), Tolu XR (Tolterodine), Flotros (Trospium), Alkaston (Potassium Magnesium Citrate), Nifutin (Nitrofurantoin) and Drolgan (Drotaverine + Aceclofenac).